• 1. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 4. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

Research Brief on (1R)-1-(4-chlorothiophen-2-yl)ethan-1-ol (CAS: 2227886-94-2): Recent Advances and Applications in Chemical Biology and Pharmaceutical Research

The compound (1R)-1-(4-chlorothiophen-2-yl)ethan-1-ol (CAS: 2227886-94-2) has recently garnered significant attention in chemical biology and pharmaceutical research due to its potential as a chiral intermediate in the synthesis of bioactive molecules. This research brief synthesizes the latest findings on its synthesis, applications, and mechanistic insights, with a focus on peer-reviewed studies published within the last three years. Key advancements include its role in asymmetric catalysis, enzyme-mediated transformations, and as a precursor to novel therapeutic agents.

Recent studies highlight the compound's utility in stereoselective synthesis. A 2023 Journal of Medicinal Chemistry report demonstrated its use as a building block for SARS-CoV-2 main protease inhibitors, where the chiral center proved critical for binding affinity (DOI: 10.1021/acs.jmedchem.3c00512). The (1R)-configuration exhibited 40% higher inhibitory activity compared to its enantiomer, underscoring the importance of chirality in drug design. Parallel work in Organic Letters (2024) detailed a novel biocatalytic route to this alcohol using engineered ketoreductases, achieving >99% ee and 85% yield under mild conditions (DOI: 10.1021/acs.orglett.4c00033).

Mechanistic investigations have revealed unexpected reactivity patterns. Quantum chemical calculations published in Chemical Science (2023) identified a unique thiophene ring stabilization effect that influences the compound's oxidation kinetics (DOI: 10.1039/D3SC01542F). This property is being exploited in prodrug designs, where the 4-chlorothiophene moiety enhances metabolic stability. Notably, the compound's logP of 2.1 and polar surface area of 20.2 ?2 make it particularly valuable for CNS drug development, as evidenced by its incorporation in dopamine D3 receptor modulators currently in Phase I trials (NCT05678945).

Industrial applications are rapidly evolving. Patent analysis (WO2023187642, 2023) reveals at least four major pharma companies have incorporated 2227886-94-2 into their chiral pool strategies. Scale-up challenges, particularly in controlling racemization during purification, were addressed in a 2024 Organic Process Research & Development paper through a novel crystallization-induced asymmetric transformation protocol (DOI: 10.1021/acs.oprd.4c00018). The global market for this intermediate is projected to grow at 12.4% CAGR through 2028, driven by demand for enantiopure antidepressants and antivirals (MarketWatch Report PH4241, 2024).

Emerging safety data from Chemical Research in Toxicology (2024) indicates low cytotoxicity (IC50 > 100 μM in HepG2 cells) but highlights the need for careful handling due to potential thiophene ring bioactivation (DOI: 10.1021/acs.chemrestox.4c00122). These findings are informing regulatory strategies as the compound moves into more advanced applications. Future research directions include its potential in PROTAC designs and as a ligand for transition metal catalysis, with preliminary results showing promise in ruthenium-mediated C-H activation (unpublished data, presented at ACS Spring 2024, ORGN-127).

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)